Lumos Deferred Long Term Liab vs Net Working Capital Analysis

LUMO Stock

USD 4.30 0.01 0.23%

Lumos Pharma financial indicator trend analysis is infinitely more than just investigating Lumos Pharma recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lumos Pharma is a good investment. Please check the relationship between Lumos Pharma Deferred Long Term Liab and its Net Working Capital accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

Deferred Long Term Liab vs Net Working Capital

Deferred Long Term Liab vs Net Working Capital Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lumos Pharma Deferred Long Term Liab account and Net Working Capital. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Lumos Pharma's Deferred Long Term Liab and Net Working Capital is -0.63. Overlapping area represents the amount of variation of Deferred Long Term Liab that can explain the historical movement of Net Working Capital in the same time period over historical financial statements of Lumos Pharma, assuming nothing else is changed. The correlation between historical values of Lumos Pharma's Deferred Long Term Liab and Net Working Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Deferred Long Term Liab of Lumos Pharma are associated (or correlated) with its Net Working Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Working Capital has no effect on the direction of Deferred Long Term Liab i.e., Lumos Pharma's Deferred Long Term Liab and Net Working Capital go up and down completely randomly.

Correlation Coefficient

-0.63

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Net Working Capital

Most indicators from Lumos Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lumos Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.At this time, Lumos Pharma's Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Issuance Of Capital Stock is likely to grow to about 761.2 K, while Tax Provision is likely to drop (44.1 K).

	2021	2022	2023	2024 (projected)
Interest Expense	484K	874K	1.0M	671.3K
Depreciation And Amortization	203K	49K	44K	41.8K

Interest Expense Depreciation And Amortization

Lumos Pharma fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Assets		-0.54	0.52	0.71	0.99	0.6	0.52	-0.99	-0.02	0.56	0.99	0.59	0.07	0.99	0.57	0.12	0.0	-0.27	-0.11	0.53	0.62	0.37	0.59	1.0	-0.23	0.58
Short Long Term Debt Total	-0.54		-0.65	-0.42	-0.56	0.24	-0.11	0.59	0.35	-0.2	-0.55	0.26	-0.69	-0.56	-0.32	0.45	-0.55	0.32	0.25	-0.39	-0.67	-0.12	0.25	-0.57	0.39	-0.06
Other Current Liab	0.52	-0.65		0.78	0.48	0.02	0.19	-0.51	-0.55	0.45	0.49	0.0	0.32	0.49	0.29	-0.2	0.02	-0.33	0.14	0.6	0.69	0.41	-0.02	0.54	-0.17	0.48
Total Current Liabilities	0.71	-0.42	0.78		0.64	0.49	0.38	-0.66	-0.14	0.81	0.66	0.48	0.08	0.65	0.31	-0.01	-0.19	-0.24	0.03	0.86	0.46	0.66	0.48	0.71	-0.06	0.5
Total Stockholder Equity	0.99	-0.56	0.48	0.64		0.58	0.48	-0.99	-0.05	0.48	0.99	0.56	0.04	0.99	0.57	0.13	0.06	-0.4	-0.12	0.45	0.66	0.21	0.57	0.99	-0.19	0.57
Property Plant And Equipment Net	0.6	0.24	0.02	0.49	0.58		0.34	-0.57	0.13	0.59	0.59	1.0	-0.49	0.59	0.12	0.47	-0.52	-0.17	-0.11	0.37	0.15	0.26	0.99	0.57	0.08	0.66
Current Deferred Revenue	0.52	-0.11	0.19	0.38	0.48	0.34		-0.46	0.38	-0.03	0.47	0.35	-0.42	0.51	0.39	0.59	-0.1	0.09	0.46	0.1	-0.03	0.38	0.34	0.52	-0.13	0.15
Net Debt	-0.99	0.59	-0.51	-0.66	-0.99	-0.57	-0.46		0.1	-0.52	-1.0	-0.55	-0.14	-1.0	-0.51	-0.06	-0.02	0.29	0.17	-0.47	-0.66	-0.31	-0.55	-0.99	0.24	-0.6
Retained Earnings	-0.02	0.35	-0.55	-0.14	-0.05	0.13	0.38	0.1		-0.05	-0.08	0.15	-0.39	-0.06	0.29	0.3	0.16	0.32	0.06	-0.06	-0.7	0.12	0.22	-0.03	0.13	-0.58
Accounts Payable	0.56	-0.2	0.45	0.81	0.48	0.59	-0.03	-0.52	-0.05		0.52	0.59	0.17	0.5	0.13	-0.11	-0.18	-0.09	-0.29	0.89	0.3	0.6	0.6	0.55	-0.13	0.42
Cash	0.99	-0.55	0.49	0.66	0.99	0.59	0.47	-1.0	-0.08	0.52		0.58	0.11	1.0	0.51	0.08	-0.01	-0.29	-0.16	0.46	0.65	0.31	0.57	0.99	-0.22	0.61
Non Current Assets Total	0.59	0.26	0.0	0.48	0.56	1.0	0.35	-0.55	0.15	0.59	0.58		-0.48	0.58	0.11	0.47	-0.54	-0.11	-0.11	0.36	0.12	0.3	0.99	0.56	0.07	0.66
Non Currrent Assets Other	0.07	-0.69	0.32	0.08	0.04	-0.49	-0.42	-0.14	-0.39	0.17	0.11	-0.48		0.09	-0.01	-0.82	0.36	0.18	-0.53	0.25	0.37	0.22	-0.5	0.1	-0.37	-0.14
Cash And Short Term Investments	0.99	-0.56	0.49	0.65	0.99	0.59	0.51	-1.0	-0.06	0.5	1.0	0.58	0.09		0.51	0.11	0.01	-0.28	-0.14	0.46	0.63	0.31	0.57	0.99	-0.23	0.6
Net Receivables	0.57	-0.32	0.29	0.31	0.57	0.12	0.39	-0.51	0.29	0.13	0.51	0.11	-0.01	0.51		0.13	0.14	-0.1	0.12	0.14	0.36	0.17	0.13	0.58	-0.16	0.05
Common Stock Total Equity	0.12	0.45	-0.2	-0.01	0.13	0.47	0.59	-0.06	0.3	-0.11	0.08	0.47	-0.82	0.11	0.13		-0.22	-0.01	0.62	-0.17	-0.19	-0.03	0.48	0.1	-0.2	0.21
Common Stock Shares Outstanding	0.0	-0.55	0.02	-0.19	0.06	-0.52	-0.1	-0.02	0.16	-0.18	-0.01	-0.54	0.36	0.01	0.14	-0.22		-0.23	-0.05	-0.02	-0.01	-0.34	-0.44	0.02	-0.31	-0.57
Non Current Liabilities Total	-0.27	0.32	-0.33	-0.24	-0.4	-0.17	0.09	0.29	0.32	-0.09	-0.29	-0.11	0.18	-0.28	-0.1	-0.01	-0.23		0.02	-0.12	-0.54	0.57	-0.15	-0.28	-0.32	-0.26
Inventory	-0.11	0.25	0.14	0.03	-0.12	-0.11	0.46	0.17	0.06	-0.29	-0.16	-0.11	-0.53	-0.14	0.12	0.62	-0.05	0.02		-0.17	-0.14	0.04	-0.11	-0.11	-0.01	0.01
Other Current Assets	0.53	-0.39	0.6	0.86	0.45	0.37	0.1	-0.47	-0.06	0.89	0.46	0.36	0.25	0.46	0.14	-0.17	-0.02	-0.12	-0.17		0.32	0.64	0.38	0.52	-0.17	0.27
Other Stockholder Equity	0.62	-0.67	0.69	0.46	0.66	0.15	-0.03	-0.66	-0.7	0.3	0.65	0.12	0.37	0.63	0.36	-0.19	-0.01	-0.54	-0.14	0.32		-0.03	0.08	0.63	-0.21	0.65
Total Liab	0.37	-0.12	0.41	0.66	0.21	0.26	0.38	-0.31	0.12	0.6	0.31	0.3	0.22	0.31	0.17	-0.03	-0.34	0.57	0.04	0.64	-0.03		0.26	0.37	-0.3	0.19
Property Plant And Equipment Gross	0.59	0.25	-0.02	0.48	0.57	0.99	0.34	-0.55	0.22	0.6	0.57	0.99	-0.5	0.57	0.13	0.48	-0.44	-0.15	-0.11	0.38	0.08	0.26		0.56	0.07	0.59
Total Current Assets	1.0	-0.57	0.54	0.71	0.99	0.57	0.52	-0.99	-0.03	0.55	0.99	0.56	0.1	0.99	0.58	0.1	0.02	-0.28	-0.11	0.52	0.63	0.37	0.56		-0.24	0.56
Short Term Debt	-0.23	0.39	-0.17	-0.06	-0.19	0.08	-0.13	0.24	0.13	-0.13	-0.22	0.07	-0.37	-0.23	-0.16	-0.2	-0.31	-0.32	-0.01	-0.17	-0.21	-0.3	0.07	-0.24		-0.03
Common Stock	0.58	-0.06	0.48	0.5	0.57	0.66	0.15	-0.6	-0.58	0.42	0.61	0.66	-0.14	0.6	0.05	0.21	-0.57	-0.26	0.01	0.27	0.65	0.19	0.59	0.56	-0.03

Click cells to compare fundamentals

Lumos Pharma Account Relationship Matchups

Lumos Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	96.8M	129.0M	100.3M	72.3M	40.6M	38.6M
Short Long Term Debt Total	1.2M	319K	557K	233K	585K	555.8K
Other Current Liab	10.2M	5.6M	3.8M	6.0M	5.6M	5.8M
Total Current Liabilities	11.8M	6.5M	5.1M	6.7M	7.0M	11.8M
Total Stockholder Equity	78.9M	116.6M	89.0M	59.6M	27.3M	25.9M
Property Plant And Equipment Net	2.4M	584K	635K	283K	603K	572.9K
Net Debt	(89.3M)	(98.4M)	(94.3M)	(55.8M)	(34.5M)	(36.2M)
Retained Earnings	(334.0M)	(66.0M)	(96.4M)	(127.5M)	(161.5M)	(169.6M)
Accounts Payable	475K	244K	612K	275K	890K	845.5K
Cash	90.5M	98.7M	94.8M	56.0M	35.1M	33.3M
Non Current Assets Total	2.4M	584K	635K	283K	603K	572.9K
Non Currrent Assets Other	735K	(584K)	(635K)	(283K)	(325.5K)	(341.7K)
Cash And Short Term Investments	90.5M	98.7M	94.8M	67.4M	36.1M	34.3M
Net Receivables	824K	26.3M	128K	223K	210K	199.5K
Common Stock Total Equity	372K	373K	12K	83K	74.7K	71.0K
Common Stock Shares Outstanding	144.7K	6.8M	8.3M	8.4M	8.1M	4.1M
Liabilities And Stockholders Equity	96.8M	129.0M	100.3M	72.3M	40.6M	38.6M
Non Current Liabilities Total	6.9M	6.1M	6M	6.2M	6.3M	6.0M
Other Current Assets	3.0M	3.5M	4.7M	4.4M	3.7M	6.2M
Other Stockholder Equity	412.5M	311.5M	185.3M	187.0M	188.7M	223.2M
Total Liab	17.9M	12.5M	11.3M	12.7M	13.3M	21.4M
Property Plant And Equipment Gross	457K	584K	635K	283K	603K	572.9K
Total Current Assets	94.4M	128.4M	99.7M	72.0M	40.0M	38.0M
Accumulated Other Comprehensive Income	(6.6M)	(7.0M)	(63.5M)	(129.0M)	0.0	(9K)
Short Term Debt	1.1M	638K	704K	466K	564K	579.2K
Common Stock	373K	374K	83K	82K	81K	77.0K
Net Tangible Assets	78.9M	116.6M	89.0M	59.6M	68.5M	104.9M
Retained Earnings Total Equity	(237.5M)	(291.0M)	(334.0M)	(66.0M)	(59.4M)	(62.4M)
Capital Surpluse	389.8M	407.2M	414.0M	182.5M	209.9M	293.4M
Property Plant Equipment	1.6M	335K	635K	283K	254.7K	242.0K

When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock:

How To Invest In Lumos

Details

Is Lumos Stock a good investment?

Details

What is Lumos Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.

You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(4.28)

Revenue Per Share

0.27

Quarterly Revenue Growth

102.714

Return On Assets

(0.70)

Return On Equity

(1.73)

The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lumos Deferred Long Term Liab vs Net Working Capital Analysis

Deferred Long Term Liab vs Net Working Capital

Deferred Long Term Liab vs Net Working Capital Correlation Analysis

Correlation Coefficient

Deferred Long Term Liab

Net Working Capital

Lumos Pharma fundamental ratios Correlations

Lumos Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lumos Pharma fundamental ratios Accounts

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.99	Total Assets
Cash	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets

Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Total Current Assets	- 0.99	Net Debt
Net Debt	- 0.99	Total Stockholder Equity
Net Debt	- 0.99	Total Assets
Common Stock Total Equity	- 0.82	Non Currrent Assets Other